超声内镜引导与内镜逆行胰胆管造影引导胆道引流治疗恶性胆道梗阻的疗效:前瞻性随机对照研究
这项前瞻性随机对照研究纳入30例恶性胆道梗阻患者,比较超声内镜引导胆道引流(EUS-BD)与内镜逆行胰胆管造影引导胆道引流(ERCP-BD)的疗效与安全性。两组技术成功率和临床成功率均无显著差异(ERCP-BD vs EUS-BD分别为100% vs 93%和93% vs 100%,P均=1.00)。EUS-BD安全性相似,但肿瘤内生长所致支架功能障碍在ERCP-BD组有4例(31%),EUS-BD组有食物嵌塞2例和支架移位2例。
要点
- EUS-BD与ERCP-BD技术成功率和临床成功率均无显著差异(P均=1.00)。
- 两组均无显著操作相关不良事件。
- ERCP-BD组4例(31%)发生肿瘤内生长所致支架功能障碍,EUS-BD组有食物嵌塞2例和支架移位2例。
核心结论
- 这项前瞻性随机对照研究提示EUS-BD的安全性相似于ERCP-BD。
- EUS-BD在缓解恶性胆道梗阻方面不优于ERCP-BD。
- EUS-BD可能肿瘤内生长病例较少,但食物嵌塞或支架移位病例可能较多。
研究设计与样本
- 前瞻性随机对照研究,共纳入30例患者,EUS-BD组和ERCP-BD组各15例。
- 评估指标包括技术成功、操作时间、临床成功和不良事件。
主要发现
- 30例患者均为肝外恶性胆道梗阻(男19例,女11例)。
- 27例为不可切除胰腺导管腺癌,1例为远端胆总管癌,2例为转移性恶性淋巴结病。
- 技术成功率和临床成功率在ERCP-BD vs EUS-BD分别为100% vs 93%和93% vs 100%,均无显著差异(P=1.00,P=1.00)。
- ERCP-BD组4例(31%)发生肿瘤内生长所致支架功能障碍,EUS-BD组有食物嵌塞2例和支架移位2例。
- 两组均无显著操作相关不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: ERCP-guided biliary drainage (ERCP-BD) is a criterion standard treatment for malignant biliary obstruction when curative surgery is not an option. Alternative methods such as percutaneous transhepatic biliary drainage would significantly lower the quality of life. EUS-guided biliary drainage (EUS-BD) has been developed and performed by experienced endoscopists. Therefore, the aims of this study were to evaluate the efficacy and safety of EUS-BD compared with ERCP in malignant biliary obstruction. METHODS: The prospective randomized controlled study was conducted, and 30 patients were enrolled: 15 for each EUS-BD and ERCP-BD arms. The technical success, procedural time, clinical success, and adverse events were evaluated. RESULTS: Thirty patients had extrahepatic malignant biliary tract obstruction (19 men, 11 women). Twenty-seven patients had unresectable pancreatic ductal adenocarcinomas, 1 patient had distal common bile duct cancer, and 2 patients had metastatic malignant lymphadenopathy. There were no significant differences both in terms of technical success rate and clinical success rate (100% vs 93% and 93% vs 100% in ERCP-BD vs EUS-BD, respectively; P = 1.00, P = 1.00). Four patients (31%) had tumor ingrowth-caused stent dysfunction in the ERCP-BD group, whereas 2 patients had food impaction and 2 patients had stent migration in the EUS-BD group. No significant procedure-related adverse events occurred in either group. CONCLUSIONS: This prospective randomized controlled study suggests that EUS-BD has similar safety to ERCP-BD. EUS-BD was not superior to ERCP-BD in terms of relief of malignant biliary obstruction. EUS-BD may have fewer cases of tumor ingrowth but may also have more cases of food impaction or stent migration. (Clinical trial registration number: NCT01421836.).
引用
- Park JK, Woo YS, Noh DH, et al. Efficacy of EUS-guided and ERCP-guided biliary drainage for malignant biliary obstruction: prospective randomized controlled study. Gastrointest Endosc. 2018. PMID: 29605722. doi:10.1016/j.gie.2018.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。